Two consecutive open heart operations in a small child with heparin-induced thrombocytopenia type II using...

Area of Science:

• Cardiology
• Hematology
• Pediatric Surgery

Background:

• Heparin-induced thrombocytopenia type II (HIT-II) is a serious immune complication of heparin exposure.
• HIT-II poses significant challenges in patients requiring anticoagulation, especially during cardiac surgery.
• Platelet glycoprotein IIb/IIIa antagonists are potential alternatives for anticoagulation in HIT-II.

Observation:

• A small child undergoing cardiac surgery presented with active heparin-induced thrombocytopenia type II.
• Tirofiban was administered as a platelet glycoprotein IIb/IIIa antagonist to manage anticoagulation needs.
• The postoperative course and clinical outcomes were closely monitored.

Findings:

• The use of tirofiban in this pediatric cardiac surgery patient with active HIT-II was feasible.
• Successful perioperative anticoagulation was achieved with tirofiban, avoiding heparin.
• The postoperative recovery was uneventful, suggesting tirofiban's utility in this context.

Implications:

• Tirofiban may be a viable therapeutic option for anticoagulation in pediatric cardiac surgery patients with HIT-II.
• This case highlights the importance of alternative anticoagulation strategies in managing HIT-II.
• Further research is warranted to establish the safety and efficacy of tirofiban in similar pediatric cases.